Cutaneous T-cell Lymphoma Clinical Trial
Official title:
Phase I/II Study of Linperlisib in Combination With Chidamide for Relapsed and Refractory Cutaneous T-cell Lymphoma: a Prospective, Single-center Study
HDAC inhibitor chidamide and PI3K inhibitor linperlisib has shown clinical activity as mono therapy in PTCL. The combination of duvelisib and romidepsin is highly active against relapsed and refractory T-cell lymphomas including cutaneous T-cell lymphomas (CTCLs). The aim of this study is to further explore the efficacy and safety of HDAC inhibitor chidamide combined with PI3K inhibitor linperlisib in the treatment of relapsed and refractory CTCLs.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
| Completed |
NCT00038025 -
A Study Of Deoxycoformycin(DCF)/Pentostatin In Lymphoid Malignancies
|
Phase 2 | |
| Not yet recruiting |
NCT02881749 -
Low Dose Total Skin Electron Beam Treatment (TSEBT) Followed by Maintenance Valchlor for Patients With Mycosis Fungoides
|
Phase 2 | |
| Completed |
NCT00744991 -
A Study for Participants With Relapsed Cutaneous T-Cell Lymphoma
|
Phase 2 | |
| Completed |
NCT00099593 -
Immunization Against Tumor Cells in Sezary Syndrome
|
Phase 2 | |
| Completed |
NCT02593045 -
Study of IPH4102 in Patients With Relapsed/Refractory Cutaneous T-cell Lymphomas (CTCL)
|
Phase 1 | |
| Recruiting |
NCT00779896 -
Tazarotene 0.1% Cream For the Treatment of Cutaneous T-Cell Lymphoma: A Prospective Study
|
Phase 1/Phase 2 | |
| Recruiting |
NCT00177268 -
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
|
||
| Completed |
NCT01728805 -
Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL
|
Phase 3 | |
| Withdrawn |
NCT00969085 -
Trial of Curcumin in Cutaneous T-cell Lymphoma Patients
|
Phase 2 | |
| Completed |
NCT00412997 -
LBH589 in Adult Patients With Advanced Solid Tumors or Cutaneous T-cell Lymphoma
|
Phase 1 | |
| Completed |
NCT00254332 -
Effect of Denileukin Diftitox on Immune System in CTCL Patients
|
N/A | |
| Recruiting |
NCT04296786 -
Sintilimab Plus Chidamide in the Treatment of Relapsed and Refractory Cutaneous T-cell Lymphoma: a Multicenter Phase II Study
|
Phase 2 | |
| Recruiting |
NCT06285370 -
A Study to Evaluate the Efficacy and Safety of KW-0761 in Chinese Subjects With Mycosis Fungoides or Sézary Syndrome Previously Treated With Systemic Therapy
|
Phase 4 | |
| Completed |
NCT00071084 -
Clinical Trial of HuMax-CD4, a New Drug to Treat Advanced Stage T-Cell Lymphoma in the Skin.
|
Phase 2 | |
| Completed |
NCT00896493 -
Ph II of Non-myeloablative Allogeneic Transplantation Using TLI & ATG In Patients w/ Cutaneous T Cell Lymphoma
|
Phase 2 | |
| Terminated |
NCT00699296 -
Study of Oral LBH589 in Patients With Cutaneous T-cell Lymphoma and Adult T-cell Leukemia/Lymphoma
|
Phase 2 | |
| Completed |
NCT02676778 -
Study of E7777 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma and Cutaneous T-cell Lymphoma
|
Phase 2 | |
| Terminated |
NCT02061449 -
Poly ICLC, Radiation, and Romidepsin for Advanced Cutaneous T Cell Lymphoma
|
Phase 1 | |
| Completed |
NCT01134341 -
Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma
|
Phase 1 |